Skip to main content
EQ
NASDAQ Life Sciences

Stockholders Approve Reverse Split and Double Authorized Shares

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$2.9
Mkt Cap
$183.357M
52W Low
$0.27
52W High
$3.1
52W Position info
974% above low
Off High info
6.5% below high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

EQ has more than doubled off its 52-week low of $0.27 on elevated volume (1.8× avg).

Summary

Equillium shareholders approved a reverse stock split and doubled the authorized common stock, setting the stage for potential significant future dilution and capital raises.


Key Events · Corporate Governance and Compliance · EQ

  • Reverse Stock Split Approved

    Stockholders approved an amendment to effect a reverse stock split of the company's common stock at a ratio in the range of 1-for-2 to 1-for-20, at the Board's discretion. This follows the proposal in the DEF 14A filed on 2026-04-15.

  • Authorized Shares Doubled

    The number of authorized common shares was increased from 200,000,000 to 400,000,000 shares. This provides the company with the ability to issue an additional 200,000,000 shares, representing a potential dilution of over 300% based on current outstanding shares.

  • Board Size Reduced

    Former director Peter Colabuono was not renominated, and the Board of Directors was reduced from seven to six members.


Analysis · EQ · Life Sciences

Equillium's stockholders approved two critical proposals: a reverse stock split (1-for-2 to 1-for-20) and an increase in authorized common stock from 200 million to 400 million shares. The increase in authorized shares provides the company with significant capacity for future equity financing, representing a potential dilution of over 300% if all newly authorized shares were issued. The reverse split is often a precursor to maintaining listing requirements or facilitating further capital raises, indicating a strategic move to address the company's stock price and capital structure.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EQ was trading at $2.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $183.4M. The 52-week trading range was $0.27 to $3.10. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EQ - Latest Insights

EQ
Nov 12, 2026, 4:20 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.34
Real-time Price: $1.27 info
Change: -$0.070 (-5%) info
Market Cap: $106.199M info
EQ
Oct 26, 2026, 5:09 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.29
Real-time Price: $1.27 info
Change: -$0.020 (-2%) info
Market Cap: $106.199M info
EQ
Oct 26, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.12
Real-time Price: $1.27 info
Change: +$0.1497 (+13%) info
Market Cap: $106.199M info
EQ
Oct 05, 2026, 5:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.42
Real-time Price: $1.27 info
Change: -$0.150 (-11%) info
Market Cap: $106.199M info
EQ
Oct 05, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.51
Real-time Price: $1.27 info
Change: -$0.240 (-16%) info
Market Cap: $106.199M info